Suzhou Basecare Medical (HKG:2170) entered into a strategic cooperation agreement with Shanghai Jinghua Medical Management for five years, a Tuesday bourse filing said.
Under the contract, the firm will provide Shanghai Jinghua Medical Management with AI-based solutions covering areas such as andrology testing, embryo culture, cryopreservation, and complex genetic diseases, with an aim to establish a world-class benchmark center for assisted reproduction.
The genetic technology research company will sell products and provide consulting services to Shanghai Jinghua Medical Management. Both parties will also collaborate on creating an intelligent reproductive genetics center.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。